Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 82 | 1 | 94 | +13 |
| Shares | 25.7M | 3.31K | 27.3M | +1.69M (+6.6%) |
| Value | $349.1M | $45.0K | $230.0M | −$119.1M (−34.1%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (22)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
Sold out (9)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Norges Bank | 660,690 | $8.99M |
| Ikarian Capital, LLC | 78,550 | $1.07M |
| Dimensional Fund Advisors LP | 73,649 | $1.00M |
| Denali Advisors LLC | 2,500 | $34.0K |
| Russell Investments Group, Ltd. | 575 | $7.00K |
| Kayne Anderson Rudnick Investment Management LLC | 39 | $1.00K |
| Bessemer Group Inc | 101 | $1.00K |
| Parallel Advisors, LLC | 80 | $1.00K |
| CWM, LLC | 36 | $0 |
Not filed for Q2 2022 yet (1)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 3,309 | $45.0K |